#EmilyRocha

VGLUT2 in Parkinson’s disease: an emerging therapeutic target Parkinson’s disease is among the most common age-related neurodegenerative disorders today and characterized by midbrain dopamine neuron degeneration. However, this cell loss is not uniform. Though...

Excited to share a new paper with #EmilyRocha and #MaryTorregrossa on mechanisms of #dopamine neuron resilience in #Parkinson's disease! We discuss the therapeutic potential of targeting the vesicular glutamate transporter 2, VGLUT2, to boost neuroprotection.

www.tandfonline.com/doi/10.1080/...